Triumeq Tablet, Film Coated
NDC Package 49702-231-13

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Triumeq (abacavir sulfate, dolutegravir sodium, lamivudine) tablets is this product contains 3 drugs: abacavir, dolutegravir, and lamivudine. This formulation utilizes a tablet, film coated delivery system. Marketed by Viiv Healthcare Company, this product is identified by NDC 49702-231 and is authorized under FDA application NDA205551.

Identification & Billing

NDC Package Code
49702-231-13
Package Description
30 TABLET, FILM COATED in 1 BOTTLE
Product Code
49702-231
11-Digit Billing Format
49702023113
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 1546888 - abacavir 600 MG / dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet
  • RxCUI: 1546888 - abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet
  • RxCUI: 1546888 - abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet
  • RxCUI: 1546894 - Triumeq 600 MG / 50 MG / 300 MG Oral Tablet
  • RxCUI: 1546894 - abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq]

Clinical Specifications

Proprietary Name
Triumeq
Non-Proprietary Name
Abacavir Sulfate, Dolutegravir Sodium, Lamivudine
Substance Name
Abacavir Sulfate; Dolutegravir Sodium; Lamivudine
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Abacavir and lamivudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Regulatory & Marketing

Labeler Name
Viiv Healthcare Company
Product Type
Human Prescription Drug
FDA Application #
NDA205551
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-22-2014
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49702-231-13 identifies a specific commercial package of 30 tablet, film coated in 1 bottle of Triumeq, a human prescription drug labeled by Viiv Healthcare Company. This tablet, film coated is formulated for oral use and contains abacavir sulfate; dolutegravir sodium; lamivudine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viiv Healthcare Company on August 22, 2014. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Abacavir and lamivudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

How is this Viiv Healthcare Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49702023113. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49702-231-13
11-Digit CMS (5-4-2)
49702-0231-13

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.